Climate change poses a fundamental threat to our livelihood and addressing the crisis through the reduction of carbon pollution is vital. The National Health Service (NHS) in the UK has committed to reducing the carbon footprint from inhaler devices by 50% by 2030, primarily through a reduction in the use of pressurised metered-dose inhalers (pMDI). The development of pMDIs utilising lower global warming potential propellants by 2025 is currently underway. This article focuses on the need to apply an individualised approach for patient outcomes whilst minimising the carbon footprint of their inhaler treatments.
Latest articlesAll articles
Cutaneous Mucormycosis Co-infection in a Patient with COVID-19
A 54-year-old male tested positive in late February on a screening COVID-19 test performed after a family member’s test had become positive. A few weeks later, they presented to the emergency room at a different hospital centre with shortness of breath and fever.
Current Perspectives and Future Directions of Repeat Pulmonary Rehabilitation Programmes in People with Chronic Obstructive Pulmonary Disease: A Narrative Review of the Literature
The benefits of pulmonary rehabilitation (PR) diminish over 12–24 months following programme completion. A repeat PR programme may potentially prevent or reverse this decline in gains and may provide additional benefits.
Modulating the Expression of Multiple Surface Receptors on Epithelial Cells and Promoting Lung Macrophage Anti-viral Functions by OM-85 Inhibits Severe Acute Respiratory Syndrome Coronavirus 2 Infection
The emergence of a new virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, in December 2019 triggered a global pandemic, forcing much of the world to adopt lockdown strategies and leading to extraordinary threats to the global healthcare system. The clinical manifestations of the disease, referred to as COVID-19, range from mild, self-limiting flu-like respiratory illness to life-threatening multi-organ failure and death.